Valuation: Glenmark Pharmaceuticals Limited

Market Cap 63TCr 660.09Cr 573.16Cr 534.4Cr 490.92Cr 928.46Cr 938.65Cr 6.3TCr 2.46TCr 31TCr 2.48TCr 2.42TCr 1,04000Cr P/E 2026
44.2x
P/E 2027 * 26.8x
Enterprise Value 59TCr 618.78Cr 537.29Cr 500.96Cr 460.2Cr 870.36Cr 879.91Cr 5.91TCr 2.31TCr 29TCr 2.32TCr 2.27TCr 97TCr EV / Sales 2026
3.51x
EV / Sales 2027 * 3.65x
Free-Float
51.04%
Yield 2026
0.12%
Yield 2027 * 0.17%
1 day+1.57%
1 week-0.08%
Current month+1.16%
1 month-0.48%
3 months-6.53%
6 months+14.76%
Current year+11.04%
1 week 2,162
Extreme 2162
2,270.2
1 month 2,162
Extreme 2162
2,326.1
Current year 1,842
Extreme 1842
2,474
1 year 1,792.6
Extreme 1792.6
2,474
3 years 722.1
Extreme 722.1
2,474
5 years 348.5
Extreme 348.5
2,474
10 years 161.65
Extreme 161.65
2,474
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2000
Director of Finance/CFO 54 27/05/2025
President - 15/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 12/05/2011
Director/Board Member 85 14/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-0.08%+10.10%+176.95% 660.09Cr
-1.22%-2.28%+19.14%+67.51% 4.95TCr
-1.75%+2.61%+59.16%+125.42% 4.01TCr
-0.08%-0.97%-2.65%+19.32% 1.24TCr
-0.79%-1.03%+15.71%+69.58% 1.18TCr
+1.44%-0.38%+31.82%+134.08% 910.08Cr
-0.26%-7.65%+36.44%-15.53% 688.06Cr
+1.59%+3.33%+15.58%+33.74% 693.63Cr
-.--%+0.14% - - 678.76Cr
-.--%-1.95% - - 572.55Cr
Average -0.05%+0.60%+23.16%+76.38% 1.56TCr
Weighted average by Cap. -0.70%+1.40%+29.20%+83.34%

Financials

2026 2027 *
Net sales 15TCr 160.96Cr 139.76Cr 130.31Cr 119.71Cr 226.4Cr 228.89Cr 1.54TCr 600.58Cr 7.65TCr 604.46Cr 591.22Cr 25TCr 17TCr 176.61Cr 153.35Cr 142.98Cr 131.35Cr 248.42Cr 251.14Cr 1.69TCr 658.98Cr 8.4TCr 663.23Cr 648.7Cr 28TCr
Net income 2.05TCr 22Cr 19Cr 17Cr 16Cr 30Cr 31Cr 206.02Cr 81Cr 1.03TCr 81Cr 79Cr 3.4TCr 2.33TCr 25Cr 21Cr 20Cr 18Cr 35Cr 35Cr 234.23Cr 92Cr 1.17TCr 92Cr 90Cr 3.87TCr
Net Debt -3.93TCr -41Cr -36Cr -33Cr -31Cr -58Cr -59Cr -394.28Cr -154.13Cr -1.96TCr -155.13Cr -151.73Cr -6.51TCr -1.45TCr -15Cr -13Cr -12Cr -11Cr -21Cr -22Cr -145.22Cr -57Cr -723.49Cr -57Cr -56Cr -2.4TCr
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
15,800
Date Price Change Volume
05/26/05 2,259.00 +1.53% 3,88,492
04/26/04 ₹2,225.00 -0.22% 4,44,946
03/26/03 ₹2,230.00 -0.17% 13,07,223
31/26/31 ₹2,233.90 +1.99% 3,71,153
30/26/30 ₹2,190.30 -3.16% 4,51,791
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,225.00INR
Average target price
2,501.36INR
Spread / Average Target
+12.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLENMARK Stock